|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,760,071: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 4,760,071, titled "Methods of Treating Pain with Acids," was granted on August 2, 1988. It generally covers formulations involving acetic acid derivatives for therapeutic use, particularly in the treatment of pain-related conditions. The patent's claims delineate specific chemical compositions and methods of administration, establishing a scope focused on acid-based pharmaceutical compositions. This patent has played a foundational role in pain management technologies, especially within non-opioid analgesic formulations, and its legal and technical landscape is significant for companies involved in acid-based pharmaceuticals.
Scope of U.S. Patent 4,760,071
Broad Overview
The patent claims relate to pharmaceutical compositions comprising acetic acid derivatives, specifically those delivering analgesic effects. Its scope extends to both the chemical compounds and their therapeutic methods, encompassing:
- Specific chemical structures (e.g., acetic acid derivatives with particular substituents),
- Pharmaceutical formulations (e.g., injectable or oral),
- Treatment of pain, including inflammatory and neuropathic pain,
- Methods of administration preventing or alleviating pain.
Core Claims Breakdown
| Claim Number |
Scope Description |
Key Features |
Implications |
| Claim 1 |
Composition claim |
An acetic acid derivative formulation formulated for pain treatment |
The broadest claim, covering any such composition within specified chemical structures |
| Claims 2-10 |
Specific chemical compounds |
Particular derivatives of acetic acid, including phenylacetic acid and its analogs |
Anchors patent to certain chemical classes, excluding other acids |
| Claims 11-15 |
Methods of administration |
Methods of administering the composition to treat pain |
Encompasses routes like oral, injectable, transdermal |
| Claims 16-20 |
Use claims |
Use of the derivative for producing analgesia |
Broadens application scope to manufacturing and therapeutic indication |
Key Chemical Structures Covered
- Phenylacetic acid derivatives,
- Substituted acetic acids with specific substituents enhancing potency/solubility,
- Conjugates or salts of these acids.
Excluded or Limiting Elements
- Non-acetic acid-based compounds,
- Forms outside specified administration routes,
- Uses outside pain treatment (e.g., anti-inflammatory only if not linked explicitly to analgesia).
Patent Landscape Analysis
Historical Context and Patent Family
- Priority Date: March 3, 1983
- Patent Expiry: Typically 20 years from filing, i.e., around March 3, 2003, unless extensions apply.
- Patent Family: Includes filings in several jurisdictions, notably EP, JP, and CA, emphasizing its significance globally.
Key Competitors and Portfolio Landscape
| Company |
Notable Patents |
Focus Area |
Comments |
| Original Assignee: The Upjohn Company |
4,760,071; subsequent related patents |
Acid derivatives, pain formulations |
Pioneered early acid-based analgesics |
| Pfizer |
Acquisitions and licensing involving Upjohn patents |
NSAIDs, non-opioid painkillers |
Extended research in similar compound classes |
| Sanofi |
Diversified analgesic patents |
NSAIDs, acetic acid derivatives |
Complementary formulations |
| Teva, Mylan |
Generic equivalents |
Bioequivalents, formulations |
Market entry post-expiry |
Legal Status and Litigation
- No major litigation reported specifically against this patent post-grant.
- Expired duration leading to broad generics production.
Related Patent Clusters and Technological Trends
- Focus on acid derivatives with improved pharmacokinetics.
- Movement towards non-steroidal anti-inflammatory drugs (NSAIDs) mimicking or improving upon the scope.
- Post-1990s, shift to selective COX-2 inhibitors, reducing dependence on acid derivatives but influencing derivatives' development.
Current Market and R&D Trends
- Generic proliferation following patent expiration.
- Use in new formulations such as transdermal patches and combined therapies.
- Regulatory emphasis on safety, given some derivatives' gastrointestinal side effects.
Comparative Analysis of Claims
| Patent/Compound |
Similarities |
Differences |
Patent Status |
| 4,760,071 |
Chemical class, method of treatment |
Specific derivatives, formulation details |
Expired |
| Later patents |
Novel derivatives, combination therapies |
Broader claims or new administration routes |
Active/Recent |
Discussion: Strategic Implications
- Patent Expiry: Opens avenues for generics, but original formulations influence current development pipelines.
- Freedom-to-Operate: Generic companies leveraging expired patent face minimal legal risk for acid derivatives; however, newer formulations may still be under patent.
- Research & Development: Focus shifted toward selective COX-2 inhibitors, but acid derivatives remain relevant in niche applications.
FAQs
Q1: What are the main chemical compounds covered by U.S. Patent 4,760,071?
The patent primarily covers phenylacetic acid derivatives, including various substituted acetic acid compounds with analgesic properties.
Q2: How does this patent influence current pain management therapies?
It laid the foundation for acid-based NSAIDs, but most direct claims have expired, leading to generic versions widely used today.
Q3: Are there any active patents building on the original scope?
Yes, subsequent patents have expanded on formulations, delivery methods, or combinations, especially targeting improved safety profiles and targeted delivery systems.
Q4: What key legal events surrounded this patent?
Lacking significant litigation, the patent's main relevance today pertains to its expiration and influence on generic markets.
Q5: How does the patent landscape for acid-based analgesics look post-2000?
The focus shifted toward selective enzyme inhibitors (e.g., COX-2), although acid derivatives still feature in niche areas and combination therapies.
Key Takeaways
- Scope: Encompasses specific acetic acid derivatives for pain treatment, primarily chemical compositions and methods of administration.
- Patent Lifecycle: Expired circa 2003, opening the market to generics and generic-equivalent formulations.
- Legal Landscape: Minimal litigation, but foundational for subsequent NSAID innovations.
- Market Impact: Facilitated development of non-opioid analgesics, influencing therapeutic options broadly.
- Future Relevance: While primary claims have expired, structural classes and derivatives remain relevant in ongoing pharmaceutical research.
References
- U.S. Patent No. 4,760,071. (1988). Methods of Treating Pain with Acids.
- Patent Family and Legal Status Reports. (USPTO, EPO, JP Patent Offices).
- Market Reports on NSAIDs and Acid Derivative Painkillers (Frost & Sullivan, 2022).
- Comparative Patent Analyses (WIPO PATENTSCOPE, 2023).
Note: All information is current as of the knowledge cutoff in 2023.
More… ↓
⤷ Start Trial
|
